JP4718174B2 - カンピロバクターグリカンおよびグリコペプチド - Google Patents

カンピロバクターグリカンおよびグリコペプチド Download PDF

Info

Publication number
JP4718174B2
JP4718174B2 JP2004525093A JP2004525093A JP4718174B2 JP 4718174 B2 JP4718174 B2 JP 4718174B2 JP 2004525093 A JP2004525093 A JP 2004525093A JP 2004525093 A JP2004525093 A JP 2004525093A JP 4718174 B2 JP4718174 B2 JP 4718174B2
Authority
JP
Japan
Prior art keywords
linked
campylobacter
antibody
jejuni
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004525093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534752A (ja
JP2005534752A5 (enExample
Inventor
ヤング、ノエル・エム．
ブリッソン、ジャン−ロバート
ケリー、ジョン・フランシス
ワトソン、デイビッド・シー
スズィマンスキ、クリスティン・エム
ジャーレル、ハロルド・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of JP2005534752A publication Critical patent/JP2005534752A/ja
Publication of JP2005534752A5 publication Critical patent/JP2005534752A5/ja
Application granted granted Critical
Publication of JP4718174B2 publication Critical patent/JP4718174B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56922—Campylobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2004525093A 2002-08-01 2003-07-30 カンピロバクターグリカンおよびグリコペプチド Expired - Fee Related JP4718174B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39973502P 2002-08-01 2002-08-01
US60/399,735 2002-08-01
PCT/CA2003/001156 WO2004013151A2 (en) 2002-08-01 2003-07-30 Campylobacter glycans and glycopeptides

Publications (3)

Publication Number Publication Date
JP2005534752A JP2005534752A (ja) 2005-11-17
JP2005534752A5 JP2005534752A5 (enExample) 2006-09-07
JP4718174B2 true JP4718174B2 (ja) 2011-07-06

Family

ID=31495764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004525093A Expired - Fee Related JP4718174B2 (ja) 2002-08-01 2003-07-30 カンピロバクターグリカンおよびグリコペプチド

Country Status (9)

Country Link
US (1) US7598354B2 (enExample)
EP (1) EP1527080B1 (enExample)
JP (1) JP4718174B2 (enExample)
CN (1) CN1671722A (enExample)
AU (1) AU2003254665C1 (enExample)
BR (1) BR0312896A (enExample)
CA (1) CA2494223C (enExample)
ES (1) ES2391525T3 (enExample)
WO (1) WO2004013151A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
AU2002952121A0 (en) * 2002-10-17 2002-10-31 Alchemia Limited Novel carbohydrate based anti-bacterials
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
JP5356807B2 (ja) 2005-05-11 2013-12-04 アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ 原核細胞由来の組み換えｎ−グリコシル化タンパク質
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ ヌクレオチド糖の改良製造法
US8999668B2 (en) 2008-01-03 2015-04-07 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
JP5925699B2 (ja) * 2010-02-11 2016-05-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ Ｎ結合型グリカン化合物
US8841099B2 (en) * 2010-04-20 2014-09-23 National Research Council Of Canada Cell-based production of nonulosonates
ES2844596T3 (es) 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
US9308246B2 (en) 2010-05-28 2016-04-12 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against Campylobacter jejuni
JP6135046B2 (ja) * 2012-04-20 2017-05-31 株式会社島津製作所 糖ペプチドの質量分析法
EP2991675B1 (en) 2013-04-05 2019-07-24 The Governors of the University of Alberta Campylobacter vaccine
EP4205553A1 (en) * 2015-01-26 2023-07-05 DSM Nutritional Products, LLC Oligosaccharide compositions for use animal feed and methods of producing thereof
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
WO2019119134A1 (en) * 2017-12-19 2019-06-27 The Governors Of The University Of Alberta Clostridium perfringens surface glycans and uses thereof
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
US20240287564A1 (en) * 2021-06-07 2024-08-29 The University Of British Columbia Acholetin biopolymers and methods for enzymatic synthesis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
WO1995005850A1 (en) * 1993-08-27 1995-03-02 Enteric Research Laboratories, Inc. Campylobacter jejuni antigens, and methods for their production and use
WO1996007753A1 (en) * 1994-09-06 1996-03-14 Bioflexin Ab Amino acid conjugate
US5840547A (en) * 1995-01-05 1998-11-24 Ramot University Authority For Applied Research & Indfustrial Development Ltd. Bioemulsifiers
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US6699705B2 (en) * 1999-02-01 2004-03-02 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3513500A (en) * 1999-03-05 2000-09-21 Trustees Of Tufts College Emulsan and emulsan analogs immunization formulations and use
US6512014B2 (en) * 2000-12-13 2003-01-28 Ramot University Authority For Applied Research And Industrial Development Limited Compositions containing bioemulsifiers and a method for their preparation
ES2561985T3 (es) * 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US9084809B2 (en) * 2005-09-21 2015-07-21 The United States Of America As Represented By The Secretary Of The Navy Immunogenic capsule composition for use as a vaccine component against Campylobacter jejuni

Also Published As

Publication number Publication date
US20060165728A1 (en) 2006-07-27
BR0312896A (pt) 2005-06-14
AU2003254665C1 (en) 2010-08-19
JP2005534752A (ja) 2005-11-17
US7598354B2 (en) 2009-10-06
ES2391525T3 (es) 2012-11-27
EP1527080B1 (en) 2012-06-20
AU2003254665B2 (en) 2010-01-28
CA2494223A1 (en) 2004-02-12
WO2004013151A3 (en) 2004-07-01
AU2003254665A1 (en) 2004-02-23
EP1527080A2 (en) 2005-05-04
WO2004013151A2 (en) 2004-02-12
CA2494223C (en) 2012-10-02
CN1671722A (zh) 2005-09-21

Similar Documents

Publication Publication Date Title
JP4718174B2 (ja) カンピロバクターグリカンおよびグリコペプチド
JPH09500092A (ja) Ｂ群れんさ球菌の多くの菌株に対する免疫を与える細胞表面タンパク質であるタンパク質Ｒｉｂ、そのタンパク質の精製方法、薬剤キットおよび医薬組成物
EP3003389B1 (en) Bordetella pertussis los-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by bordetella pertussis
US9221898B2 (en) N-linked glycan compounds
US11267841B2 (en) Enterococcus faecalis and/or Enterococcus faecium antigen
EP3535276A2 (en) Capped oligosaccharides comprising seven or more units of 4,6-dideoxy-4-acylamido-alpha-pyranose and conjugates thereof as vaccines against infections caused by brucella organisms
CA2224460C (en) Process for producing gm2 specific antibodies
EP1747262B1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
KR20180074804A (ko) 마이코플라즈마 감염증용 백신
Xiao et al. Antigenicity evaluation of synthetic α-(1, 3)-linked D, D-heptoglycan of Helicobacter pylori serotype O6 lipopolysaccharide
EP2334706B1 (en) Identification of a conserved inner core oligosaccharide region of moraxella catarrhalis lipopolysaccharide as a vaccine antigen
Pan et al. Synthesis and immunological evaluation of the lipopolysaccharide outer core of Salmonella for potential broad-spectrum protection against multiple Salmonella serovars
EA046636B1 (ru) Способы получения биоконъюгатов полисахаридных о-антигенов e. coli, их композиции и способы их применения
HK1133267B (en) Enterococcus faecalis and/or enterococcus faecium antigen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100310

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110331

R150 Certificate of patent or registration of utility model

Ref document number: 4718174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees